Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVOEYE: AVT06 vs Eylea in Wet AMD
NCT05155293Phase 3Completed
- Sponsor
- Alvotech
- Start
- Jun 2022
- Primary completion
- Nov 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 5
01
Overview
A Phase 3 trial of AVT06 in neovascular age-related macular degeneration (NVAMD), sponsored by Alvotech. Started Jun 2022; status: completed.
02
Drugs
AVT06
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05155293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155293.